Where psychiatry meets metabolism.

Metabolic psychiatry treats mental health conditions by also addressing the metabolic systems that drive them, including insulin signaling, inflammation, the gut-brain axis, and reward circuitry. In practice, that means using GLP-1 medications, targeted lab work, and conventional psychiatric medications as one integrated plan rather than parallel silos.

Yes. Any licensed physician, including a psychiatrist, can prescribe semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and, once FDA-approved, newer agents like retatrutide (currently investigational) when clinically appropriate. The advantage of having a psychiatrist prescribe is that GLP-1 medications also influence mood, cravings, addictive behavior, and cognition, all of which sit squarely inside psychiatric care.

A weight-loss clinic typically focuses on the scale. This practice treats GLP-1 medications as psychiatric and neurometabolic tools used for binge eating, alcohol cravings, anxiety, ADHD-related dysregulation, and weight gain caused by antidepressants, mood stabilizers, or antipsychotics. The same clinician manages both your psych meds and your metabolic plan, so they're never working against each other.

Most psychiatric medications can be safely continued alongside GLP-1 therapy, but specific interactions and dose adjustments need a careful review. That review is the first thing covered in the initial visit (current meds, recent labs, history, and goals) before anything is added or changed. See the main practice page for the broader range of psychiatric care offered alongside metabolic work.

Not at this time. Selank, Semax, BPC-157, and KPV are not FDA-approved, and as of 2026 none can be lawfully compounded by U.S. pharmacies. An FDA advisory committee voted in July 2026 to recommend allowing Semax, BPC-157, and KPV in compounding, but the FDA has not yet acted on that recommendation. If you’re curious about them, or already using something ordered online, we’ll go through the evidence and the risks honestly, and revisit prescribing if they become lawfully available.

Coverage for GLP-1 medications depends on your plan, your diagnosis, and the specific drug. Many commercial plans cover semaglutide or tirzepatide for type 2 diabetes or qualifying obesity criteria; coverage for off-label psychiatric use is less common. The visit itself is out-of-network, with superbills provided for reimbursement.

Standard panels typically include fasting insulin, HbA1c, lipid panel, hs-CRP, comprehensive metabolic panel, thyroid function, vitamin D, B12, ferritin, and sex hormones when relevant. Labs are repeated at intervals to track response and adjust the plan.

Yes. This is one of the most common reasons people come to the practice. Options range from switching to a more weight-neutral psychiatric medication, adding a GLP-1 agent, or both. The plan is built around staying psychiatrically stable while reversing the metabolic side effect. The main practice handles the underlying psychiatric care for ADHD, anxiety, and depression that often sits alongside this conversation.

Yes, for established patients within New York State. Initial evaluations are typically in-person at the Union Square office (201 E 16th St) so the first assessment, vitals, and exam are done together.